Augmedix Q1 revenue up 40% to $13.5M; guides FY24 lower on AI purchasing slowdown

Augmedix, Inc.

2024-Q1 EPS reported -$0.12 revenue$13,471,000

Revenue $13.5M (+40% YoY); gross margin 47.1% (up 150 bps).
Net loss $6.5M vs $5.2M; adjusted EBITDA loss $5.1M vs $4.3M.
Dollar-based Net Revenue Retention 143% vs 136% for Health Enterprise.
CEO cites slower purchasing commitments; full-year revenue outlook lowered.
Cash $37.3M; HCA Healthcare planning expansion of Augmedix Go to more EDs.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Augmedix, Inc. reported first quarter ended March 31, 2024 results: revenue $13,471, net income $(6,499), EPS $(0.12).

Period: first quarter ended March 31, 2024
Revenue: $13,471
Net income: $(6,499)
EPS: $(0.12)
Result: reported results

Exact text from the filing

healthcare systems and clinicians who are helping us optimize our suite of solutions.” 1 Three Months Ended March 31, Financial Highlights: 2024 2023 Change Revenues $13,471 $9,628 40% Gross profit $6,341 $4,386 45% Gross margin 47.1 % 45.6 % 150 bps Net loss $(6,499) $(5,239) (24)% Loss per share $(0.12) $(0.14) 14% Adjusted EBITDA (non-GAAP)

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001628280-24-022885

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.